ArticleRSC advances2026
Peptide-AuNP-drug conjugate-integrated photocrosslinkable hydrogel with pH/glutathione dual-responsive drug delivery and NIR-triggered heating for combined chemo-photothermal treatment.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX)-based chemotherapy for breast cancer is frequently compromised by systemic toxicity, poor tumor selectivity, and multidrug resistance, underscoring the need for localized and multimodal therapeutic strategies. Here, we developed an injectable peptide-gold-drug (PAD) conjugate-integrated photocrosslinked methacry-loyl hyaluronic acid (HAMA/PAD) hydrogel that couples stimuli-responsive chemotherapy with NIR-triggered photothermal therapy in a single platform. Two-dimensional peptide nanosheets (PNSs) self-assembled from Fmoc-FKKGSHC served as multifunctional molecular scaffolds for the spatial organization of gold nanoparticles (AuNPs) and thiolated DOX (DOX-SH) through Au-S coordination, generating PAD conjugates. This hierarchical nano-to-macro integration enables the HAMA/PAD hydrogel to function simultaneously as an injectable depot and a localized tumor microenvironment. The resulting HAMA/PAD hydrogel exhibited an interconnected porous architecture, shear-thinning behaviour, compatible with syringe-based delivery prior to photocrosslinking, and a storage modulus of approximately 100 Pa. Importantly, PAD exhibited efficient DOX incorporation, while the hydrogel provided pH- and glutathione (GSH)-responsive drug release, offering stimuli-dependent control over DOX availability. Under 808 nm NIR irradiation, HAMA/PAD rapidly generated localized hyperthermia, reaching approximately 55 °C, and maintained stable photothermal performance over repeated irradiation cycles. Additionally, the hydrogel exhibited good cytocompatibility toward L929 fibroblasts, whereas combined HAMA/PAD and NIR treatment reduced 4T1 breast cancer cell viability to approximately 10%, demonstrating a pronounced chemo-photothermal effect. Overall, this study establishes a PNS-enabled strategy for integrating nanoscale drug/photothermal components within an injectable hydrogel depot, providing a versatile platform for localized, stimulus-responsive, and combined chemo-photothermal treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.